Morbidity · people undergoing laparoscopic cholecystectomy.
It is very uncertain whether various interventions changes morbidity compared with control (very low certainty).
1 finding from 1 review
Proportion discharged as day surgery · people undergoing laparoscopic cholecystectomy.
It is very uncertain whether various interventions changes proportion discharged as day‐surgery compared with control (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing laparoscopic cholecystectomy.
1 finding from 1 review
Pain (4 to 8 hours) · people undergoing laparoscopic cholecystectomy.
1 finding from 1 review
Pain (9 to 24 hours) · people undergoing laparoscopic cholecystectomy.
1 finding from 1 review
All‐cause mortality · people undergoing laparoscopic cholecystectomy.
1 finding from 1 review
Opioids versus NSAIDs · people undergoing laparoscopic cholecystectomy.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Hepatocellular carcinoma · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Chronic HCV infection†‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ MTH‐68/B vaccine versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ MTH‐68/B vaccine versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (proportion) ‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (number) ‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
Health‐related quality of life · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Liver transplantation · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Decompensated liver disease · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cirrhosis · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes mortality compared with placebo (very low certainty).
1 finding from 1 review